Who owns Hemab Therapeutics Holdings, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of COAG from SEC Form 13F filings across 89 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 89 institutions disclosed 39.9M shares of Hemab Therapeutics Holdings, Inc. worth $1.23B — about 85.3% of shares outstanding; the largest disclosed holder is RA CAPITAL MANAGEMENT, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
89
13F holders
$1.23B
value, 2026 filers
85.3%
of shares outstanding (39.9M sh)
42
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of COAG's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 7.8M | $240.8M | 2.4% | 16.7% | 0.0% |
| 2 | NOVO HOLDINGS A/S | 4.2M | $128.9M | 8.7% | 8.9% | 0.0% |
| 3 | FMR LLC | 3.7M | $114.8M | 0.0% | 8% | +0.7% |
| 4 | Capital International Investors | 3.6M | $111.1M | 0.0% | 7.7% | -0.1% |
| 5 | Deep Track Capital, LP | 3.6M | $110.6M | 1.8% | 7.7% | -0.4% |
| 6 | Siren, L.L.C. | 2.4M | $73.0M | 1.7% | 5.1% | +13.4% |
| 7 | Avoro Capital Advisors LLC | 1.9M | $58.4M | 0.6% | 4.1% | -1.7% |
| 8 | Bain Capital Life Sciences Investors, LLC | 1.6M | $50.9M | 3.4% | 3.5% | 0.0% |
| 9 | BlackRock, Inc. | 1.4M | $43.1M | 0.0% | 3% | +392.9% |
| 10 | JPMORGAN CHASE & CO | 932,857 | $30.4M | 0.0% | 2% | -19.1% |
| 11 | STATE STREET CORP | 927,245 | $28.6M | 0.0% | 2% | +1105.8% |
| 12 | VANGUARD CAPITAL MANAGEMENT LLC | 774,064 | $23.9M | 0.0% | 1.7% | -0.9% |
| 13 | PRICE T ROWE ASSOCIATES INC /MD/ | 757,132 | $23.4M | 0.0% | 1.6% | +1.5% |
| 14 | Driehaus Capital Management LLC | 708,166 | $21.8M | 0.2% | 1.5% | -1.1% |
| 15 | Paradigm Biocapital Advisors LPNEW | 629,347 | $19.4M | 0.4% | 1.3% | new |
| 16 | Rock Springs Capital Management LP | 575,432 | $17.7M | 1.0% | 1.2% | 0.0% |
| 17 | Bellevue Group AG | 548,935 | $16.9M | 0.4% | 1.2% | -0.2% |
| 18 | GEODE CAPITAL MANAGEMENT, LLC | 502,042 | $15.5M | 0.0% | 1.1% | +137.0% |
| 19 | Affinity Asset Advisors, LLC | 420,000 | $13.0M | 0.5% | 0.9% | +204.3% |
| 20 | Parkman Healthcare Partners LLC | 329,251 | $10.2M | 0.9% | 0.7% | +631.7% |
| 21 | DEERFIELD MANAGEMENT COMPANY, L.P. | 275,000 | $8.5M | 0.1% | 0.6% | 0.0% |
| 22 | Schonfeld Strategic Advisors LLC | 169,101 | $5.2M | 0.0% | 0.4% | +1463.9% |
| 23 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 164,825 | $5.1M | 0.0% | 0.4% | +52.3% |
| 24 | NORTHERN TRUST CORP | 151,558 | $4.7M | 0.0% | 0.3% | +274.3% |
| 25 | Woodline Partners LP | 150,040 | $4.6M | 0.0% | 0.3% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.